Firm-Level Exposure to Epidemic Diseases: Covid-19, Sars, and H1n1
83 Pages Posted: 13 Apr 2020 Last revised: 24 Sep 2022
There are 4 versions of this paper
Firm-Level Exposure to Epidemic Diseases: COVID-19, SARS, and H1N1
Firm-Level Exposure to Epidemic Diseases: COVID-19, SARS, and H1N1
https://doi.org/10.36687/inetwp119
Firm-Level Exposure to Epidemic Diseases: Covid-19, Sars, and H1n1
Firm-Level Exposure to Epidemic Diseases: Covid-19, Sars, and H1n1
Date Written: April 2020
Abstract
We construct text-based measures of the primary concerns listed firms associated with the spread of COVID-19 and other epidemic diseases. We identify which firms perceive to lose or gain from a given epidemic and textually decompose the epidemic's effect on the firm's demand and supply. We find that the effects of COVID-19 manifest as a simultaneous shock to demand and supply, with both shocks affecting firms' market valuations in equal measure on average. By contrast, demand-related impacts appear more important in accounting for the observed collapse in firm-level investment during the COVID-19 crisis.
Suggested Citation: Suggested Citation